Last Updated on December 21, 2022
Preparation
- Tablet
Clinical Use
Anti-ischemic / anti-angina. As ADD-ON therapy for the symptomatic treatment of patients with stable angina pectoris
Mechanism of Action
Trimetazidine prevents a decrease in intracellular ATP levels. This ensures proper functioning of ionic pumps and transmembrane sodium-potassium flow.
Trimetazidine inhibits β-oxidation of fatty acids. This enhances glucose oxidation.
Energy obtained during glucose oxidation requires LESS OXYGEN CONSUMPTION than during ß-oxidation process.
Thus, it maintains proper energy metabolism during myocardial cellular ischaemia.
Dose
- T Vastarel MR 35 mg BD
- T Vastarel MR 35 mg OD (creatinine clearance 30 – 60)
Contraindications
- Parkinson disease
- Creatinine clearance <30